Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

JNGLX Janus Henderson Global Life Sciences D

  • Fund
  • JNGLX
  • Price as of: Oct 20, 2017
  • $56.13
  • - $0.07
  • - 0.13%
  • Category
  • Health & Biotech Equities

JNGLX - Profile

Vitals

  • YTD Return 24.0%
  • 3 Yr Annualized Return 9.5%
  • 5 Yr Annualized Return 20.1%
  • Net Assets $3.75 B
  • Holdings in Top 10 27.2%

52 WEEK LOW AND HIGH

$56.13
$43.49
$57.41

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.84%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 41.00%

TRADING FEES

  • Max Redemption Fee 2.00%

Min Investment

Closed to new investors as of 2010-02-12

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 24.0%
  • 3 Yr Annualized Total Return 9.5%
  • 5 Yr Annualized Total Return 20.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.30%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name Janus Henderson Global Life Sciences Fund
  • Fund Family Name Janus Henderson
  • Inception Date Dec 31, 1998
  • Shares Outstanding N/A
  • Share Class D
  • Currency USD
  • Domiciled Country United States
  • Manager Andrew Acker

Fund Description

The Janus Global Life Sciences Fund Class D (JNGLX) is a low-cost, actively managed fund focused on the health care sector. The fund holds a wide range of health care-related equities from around the world and can invest in any market-cap size. JNGLX balances its investments in the biotech, traditional pharmaceuticals and health care equipment/services sphere in order to help reduce volatility.

As a specialized health care fund, JNGLX should only be used as a satellite position in a broader equity portfolio. The fund is managed by Janus Capital Management.

JNGLX - Performance

Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 24.0% -14.9% 38.2% 39.29% 2
1 Yr 14.8% -14.8% 37.9% 54.95% 3
3 Yr 9.5% * -7.5% 18.6% 37.96% 2
5 Yr 20.1% * 9.3% 20.6% 5.83% 1
10 Yr 12.9% * 6.1% 17.7% 29.13% 2

* Annualized


Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -13.4% -29.8% 2.6% 40.91% 3
2015 -0.8% -20.4% 14.5% 30.91% 2
2014 22.3% -5.8% 33.7% 20.00% 1
2013 43.8% -2.6% 65.2% 37.61% 2
2012 20.3% -5.3% 36.5% 21.36% 2

Total Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 24.0% -14.9% 38.2% 39.64% 2
1 Yr 14.8% -18.3% 35.9% 45.45% 3
3 Yr 9.5% * -14.2% 18.6% 37.04% 2
5 Yr 20.1% * 9.1% 20.6% 4.85% 1
10 Yr 12.9% * 6.1% 17.7% 28.16% 2

* Annualized


Total Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%) Quintile
2016 -13.4% -25.1% 6.3% 44.95% 3
2015 9.1% -16.6% 39.1% 33.03% 2
2014 45.6% -5.8% 100.0% 11.93% 1
2013 101.3% -5.1% 398.7% 15.74% 1
2012 60.8% -2.6% 475.8% 17.00% 1

NAV & Total Return History

JNGLX - Holdings

Filings data as of: Jun 30, 2017

Concentration Analysis

JNGLX Category Low Category High JNGLX % Rank Quintile
Net Assets 3.75 B 19.4 M 48.1 B 8.04% 1
Number of Holdings 96 31 361 12.50% 2
Net Assets in Top 10 985 M 11 M 20.8 B 11.61% 2
Weighting of Top 10 27.2% 19.8% 74.1% 35.71% 5

Top 10 Holdings

  1. Celgene Corp 2.89%
  2. Sanofi SA 2.87%
  3. Aetna Inc 3.00%
  4. Eli Lilly and Co 3.55%
  5. AstraZeneca PLC 2.69%
  6. Shire PLC ADR 2.88%
  7. Boston Scientific Corp 2.13%
  8. Regeneron Pharmaceuticals Inc 2.59%
  9. Allergan PLC 2.40%
  10. Anthem Inc 2.21%

Asset Allocation

Weighting Category Low Category High JNGLX % Rank Quintile
Stocks
93.99% 91.83% 100.05% 34.82% 5
Cash
3.00% -0.05% 5.66% 8.04% 2
Other
2.43% -5.64% 5.15% 2.68% 1
Convertible Bonds
0.57% 0.00% 0.57% 0.89% 1
Preferred Stocks
0.00% 0.00% 2.60% 7.14% 3
Bonds
0.00% 0.00% 4.69% 5.36% 3

Stock Sector Breakdown

Weighting Category Low Category High JNGLX % Rank Quintile
Healthcare
90.45% 12.17% 99.98% 33.93% 5
Technology
2.72% 0.00% 61.82% 11.61% 2
Industrials
0.82% 0.00% 8.83% 3.57% 1
Utilities
0.00% 0.00% 1.12% 1.79% 3
Real Estate
0.00% 0.00% 1.59% 2.68% 3
Financial Services
0.00% 0.00% 4.83% 6.25% 3
Energy
0.00% 0.00% 0.00% 0.89% 3
Communication Services
0.00% 0.00% 0.57% 1.79% 3
Consumer Defense
0.00% 0.00% 1.54% 11.61% 4
Consumer Cyclical
0.00% 0.00% 6.59% 6.25% 3
Basic Materials
0.00% 0.00% 2.25% 4.46% 3

Stock Geographic Breakdown

Weighting Category Low Category High JNGLX % Rank Quintile
US
77.05% 64.49% 99.98% 31.25% 4
Non US
16.94% 0.00% 35.11% 6.25% 1

JNGLX - Expenses

Operational Fees

JNGLX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.84% 0.10% 4.31% 58.93% 1
Management Fee 0.64% 0.09% 1.25% 11.61% 2
12b-1 Fee N/A 0.00% 1.00% N/A N/A
Administrative Fee 0.12% 0.01% 0.40% 7.69% 3

Sales Fees

JNGLX Fees (% of AUM) Category Low Category High JNGLX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

JNGLX Fees (% of AUM) Category Low Category High JNGLX Rank Quintile
Max Redemption Fee 2.00% 0.75% 2.00% 2.27% 5

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JNGLX Fees (% of AUM) Category Low Category High JNGLX Rank Quintile
Turnover 41.00% 0.00% 699.00% 15.18% 3

JNGLX - Distributions

Dividend Yield Analysis

JNGLX Category Low Category High JNGLX % Rank Quintile
Dividend Yield 0.0% 0.01% 0.94% 66.67% 4

Dividend Distribution Analysis

JNGLX Category Low Category High Category Mode
Dividend Distribution Frequency Semi-Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

JNGLX Category Low Category High JNGLX % Rank Quintile
Net Income Ratio 0.30% -2.22% 1.40% 13.39% 1

Capital Gain Distribution Analysis

JNGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

JNGLX - Managers

Andrew Acker

Manager

Start Date

May 01, 2007

Tenure

10.42

Tenure Rank

11.7%

Andy Acker is a Portfolio Manager on the Janus Global Life Sciences strategy, a position he has held since 2007. He also serves as co-team leader of the health care sector research team and as a Research Analyst covering the biotechnology sector. Mr. Acker served as assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007 and as co-portfolio manager of the Janus Aspen Global Life Sciences Portfolio from 2004 to 2007. Mr. Acker joined Janus in 1999 as a research analyst, focusing on companies in the biotechnology and pharmaceutical industries. Prior to Janus, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA from Harvard Business School, graduating with honors. Mr. Acker holds the Chartered Financial Analyst designation.


Ethan Lovell

Manager

Start Date

Jan 12, 2016

Tenure

1.72

Tenure Rank

22.8%

Ethan Lovell is a Portfolio Manager responsible for co-managing the Janus Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries and serves as a co-team leader of the health care sector research team. Prior to joining Janus as a research analyst in 2007, Mr. Lovell was a director at ClearBridge Advisors covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director, then managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. He received his bachelor of arts from Bowdoin College with a double major in chemistry and economics and his MBA from Tulane University.


Tenure Analysis

Category Low

0.3

Category High

20.1

Category Average

9.01

Category Mode

2.8